Abbisko Cayman Limited 8ZD.F Stock
Abbisko Cayman Limited Price Chart
Abbisko Cayman Limited 8ZD.F Financial and Trading Overview
| Abbisko Cayman Limited stock price | 0.4 EUR |
| Previous Close | 0.4 EUR |
| Open | 0.4 EUR |
| Bid | 0 EUR x N/A |
| Ask | 0 EUR x N/A |
| Day's Range | 0.4 - 0.4 EUR |
| 52 Week Range | 0.32 - 0.5 EUR |
| Volume | 2K EUR |
| Avg. Volume | 0 EUR |
| Market Cap | 258.52M EUR |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.09 EUR |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
8ZD.F Valuation Measures
| Enterprise Value | -2076710400 EUR |
| Trailing P/E | N/A |
| Forward P/E | N/A |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | N/A |
| Price/Book (mrq) | 0.10927152 |
| Enterprise Value/Revenue | N/A |
| Enterprise Value/EBITDA | 4.216 |
Trading Information
Abbisko Cayman Limited Stock Price History
| Beta (5Y Monthly) | N/A |
| 52-Week Change | 5.31% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 0.5 EUR |
| 52 Week Low | 0.32 EUR |
| 50-Day Moving Average | 0.4 EUR |
| 200-Day Moving Average | 0.4 EUR |
8ZD.F Share Statistics
| Avg. Volume (3 month) | 0 EUR |
| Avg. Daily Volume (10-Days) | 0 EUR |
| Shares Outstanding | 647.43M |
| Float | 298.54M |
| Short Ratio | N/A |
| % Held by Insiders | 27.26% |
| % Held by Institutions | 29.62% |
| Shares Short | N/A |
| Short % of Float | N/A |
| Short % of Shares Outstanding | N/A |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | December 31, 2022 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | 0% |
| Gross Margin | 0% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -12.081% |
| Return on Equity (ttm) | -20.30% |
Income Statement
| Revenue (ttm) | N/A |
| Revenue Per Share (ttm) | N/A |
| Quarterly Revenue Growth (yoy) | N/A |
| Gross Profit (ttm) | N/A |
| EBITDA | -492620000 EUR |
| Net Income Avi to Common (ttm) | -495606016 EUR |
| Diluted EPS (ttm) | -0.36 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 2.38B EUR |
| Total Cash Per Share (mrq) | 3.67 EUR |
| Total Debt (mrq) | 45.58M EUR |
| Total Debt/Equity (mrq) | 1.94 EUR |
| Current Ratio (mrq) | 22.386 |
| Book Value Per Share (mrq) | 3.624 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -343896992 EUR |
| Levered Free Cash Flow (ttm) | -195994256 EUR |
Profile of Abbisko Cayman Limited
| Country | Germany |
| State | N/A |
| City | Shanghai |
| Address | Building 3 |
| ZIP | N/A |
| Phone | 86 21 6891 2098 |
| Website | https://www.abbisko.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 250 |
Abbisko Cayman Limited, a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule oncology therapies in Mainland China. The company's product candidates are primarily small molecules that focus on small molecule precision oncology and small molecule immuno-oncology therapeutic areas. It is also involved in the research and development in areas of biomedical and biotechnology; and provision of technical and technical consultation services. Abbisko Cayman Limited has co-discovery collaboration agreement with Eli Lilly and Company for the discovery, development, and commercialization of novel molecules; and BeiGene, Ltd. on the combination therapy of fexagratinib and tislelizumab, an anti-PD-1 antibody for treating urothelial cancer with FGFR2/3 genetic alterations. The company was founded in 2016 and is headquartered in Shanghai, the People's Republic of China.
Q&A For Abbisko Cayman Limited Stock
What is a current 8ZD.F stock price?
Abbisko Cayman Limited 8ZD.F stock price today per share is 0.4 EUR.
How to purchase Abbisko Cayman Limited stock?
You can buy 8ZD.F shares on the Frankfurt exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Abbisko Cayman Limited?
The stock symbol or ticker of Abbisko Cayman Limited is 8ZD.F.
Which industry does the Abbisko Cayman Limited company belong to?
The Abbisko Cayman Limited industry is Biotechnology.
How many shares does Abbisko Cayman Limited have in circulation?
The max supply of Abbisko Cayman Limited shares is 706.72M.
What is Abbisko Cayman Limited Price to Earnings Ratio (PE Ratio)?
Abbisko Cayman Limited PE Ratio is now.
What was Abbisko Cayman Limited earnings per share over the trailing 12 months (TTM)?
Abbisko Cayman Limited EPS is -0.09 EUR over the trailing 12 months.
Which sector does the Abbisko Cayman Limited company belong to?
The Abbisko Cayman Limited sector is Healthcare.